从肥胖患者收集的腹部脂肪组织样本的新陈代谢 - - 批判性审查
1Division of Biochemistry and Biogerontology, Department of Geriatrics, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Debowa 3 Street, 85626, Bydgoszcz, Poland. alina.jaroch@cm.umk.pl.
Molecular and cellular biochemistry
|September 30, 2025
概括
代谢学研究显示,皮下 (SAT) 和内脏 (VAT) 脂肪组织之间的脂肪代谢存在显著差异. 目前的研究局限性阻碍了可靠的发现,需要标准化方法来研究肥胖.
科学领域:
- 代谢学 代谢学 代谢学
- 肥胖问题研究研究
- 脂肪组织生物学 脂肪组织生物学
背景情况:
- 肥胖是一种复杂的代谢障碍,与胰岛素抵抗,心血管疾病和代谢综合征有关.
- 脂肪组织储存,包括皮下 (SAT) 和内脏 (VAT) 脂肪,具有不同的代谢作用,但表现出显著的异质性.
- 代谢学提供了对脂肪组织的分子洞察力,但方法上的不一致性限制了当前的发现.
研究的目的:
- 对肥胖症中脂肪组织的现有代谢学研究进行批判性审查.
- 在VAT和SAT之间识别脂质代谢,能量平衡和炎症的差异.
- 突出局限性,并为未来的肥胖代谢学研究提出改进建议.
主要方法:
- 对代谢学研究的批判性文献评论,重点关注VAT和SAT.
- 分析代谢特征的差异,包括脂质代谢和炎症.
- 评估研究设计的局限性和方法上的不一致性.
主要成果:
- 关于VAT (促炎性,脂解性) 和SAT (脂存储) 的概括忽略了仓库特定的变化和异质性.
- 在VAT和SAT之间,在脂质代谢,能量恒温和与炎症相关的途径中发现了关键的差异.
- 现有的研究存在方法上的局限性,设计不一致,缺乏多样化的群体.
结论:
- 改善代谢分析的标准化对于可靠的脂肪组织研究至关重要.
- 未来的研究需要多样化的群体和强大的纵向研究,以获得精确的见解.
- 解决这些问题将提高对脂肪组织在肥胖中的作用的理解,并为临床管理策略提供信息.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247


